Trials / Completed
CompletedNCT00195845
A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Cambridge Health Alliance · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine if galantamine augmentaion improves cognition in euthymic bipolar patients. In addition, the effect of galantamine on clinical measures of functioning and psychopathology will also be assessed.
Detailed description
The study length is 12 to 24 weeks depending on whether patients enter the crossover. Study also involves 3 neuropsychology testings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galantamine | |
| DRUG | Placebos |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2006-09-01
- Completion
- 2007-02-01
- First posted
- 2005-09-20
- Last updated
- 2017-04-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00195845. Inclusion in this directory is not an endorsement.